英科医疗科技股份有限公司 2025 年第三季度报告 证券代码：300677 证券简称：英科医疗 公告编号：2025-148 英科医疗科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 期增减 | 比上年同期增减 | | | 营业收入（元） | 2,511,275,781.81 | -2.90% | 7,424,714,825.22 | 4.60% | | 归属于上市公司股东的净利润 （元） | 213,970,729.66 | 113.04% | 924,410,713.59 | 34.47% | | 归属于上市公司股东的扣除非经 常性损益的净利润（元） | 84,280,208.92 | -25.87% | 484,481,437.92 | -19.32% | | ...

Group 1 - The core viewpoint of the news is that Yingke Medical's stock has increased by 5.01%, reaching a price of 42.13 CNY per share, with a trading volume of 565 million CNY and a turnover rate of 2.95%, resulting in a total market capitalization of 27.586 billion CNY [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company operates in three main business segments: personal protection, rehabilitation care, and other products [1] - The revenue composition of Yingke Medical is as follows: personal protection accounts for 91.47%, rehabilitation care for 4.75%, and other products for 3.77% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund ranks among the top shareholders of Yingke Medical. The Southern CSI 500 ETF (510500) increased its holdings by 967,200 shares in the second quarter, bringing its total to 6.698 million shares, which represents 1.43% of the circulating shares [2] - The estimated floating profit for the Southern CSI 500 ETF today is approximately 13.4629 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion CNY. Year-to-date returns are 28.62%, ranking 1823 out of 4219 in its category, while the one-year return is 28.52%, ranking 1678 out of 3877 [2]

证券日报网讯 10月24日晚间，英科医疗发布公告称，公司于近日接到公司控股股东刘方毅先生的通 知，获悉刘方毅先生将其所持有的公司部分股份办理了质押解除手续，解除质押股数为1，280，000 股。 （文章来源：证券日报） ...

Core Viewpoint - Inke Medical announced a significant investment of $70 million (approximately 500 million RMB) in Warburg Pincus Global Growth 15, L.P., aiming to enhance capital efficiency and financial returns while promoting deep integration of capital and industry [1][3]. Investment Details - The partnership fund has a target fundraising size of $17 billion, with Inke Medical participating as a limited partner (LP) [1][3]. - The fund's investment focus includes healthcare, energy transition, business services, industrial, technology, consumer sectors, and sustainable development [3]. Financial Performance - In the first half of 2025, Inke Medical reported revenue of 4.913 billion RMB, an increase of 8.9% year-on-year [3]. - The net profit attributable to shareholders was 710 million RMB, reflecting a year-on-year growth of 21.02% [3]. - The net cash flow from operating activities reached 745 million RMB, a significant increase of 170.15% compared to the same period last year [3]. - As of June 30, 2025, the total assets amounted to 39.515 billion RMB, up 14.10% from the end of the previous year [3]. - The cash and cash equivalents balance was 11.738 billion RMB, with trading financial assets totaling 10.857 billion RMB, bringing the combined total to 22.595 billion RMB [3]. Company Overview - Inke Medical Technology Co., Ltd. is a high-tech manufacturing enterprise focused on the research, production, and marketing of medical device consumables [3]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in July 2017 and offers a range of products including medical consumables, health care devices, and therapeutic care products [3].

Group 1 - The core point of the news is that Yingke Medical (SZ 300677) announced that as of the announcement date, Liu Fangyi has pledged a total of 29.87 million shares, accounting for 12.89% of his total holdings [1] - Yingke Medical's revenue composition for the year 2024 is entirely from medical devices, with a 100.0% share [2] - As of the time of reporting, Yingke Medical has a market capitalization of 26.3 billion yuan [3]

关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于近日接到公 司控股股东刘方毅先生的通知，获悉刘方毅先生将其所持有的公司部 分股份办理了质押解除手续。现将具体内容公告如下： 注：本公告总股本数以截至 2025 年 10 月 23 日公司最新总股本 654,793,743 股为计算标 准。 二、股东股份累计质押的情况 截至本公告披露日，刘方毅先生所持股份累计质押情况如下： 证券代码：300677 证券简称：英科医疗 公告编号：2025-146 英科医疗科技股份有限公司 三、其他说明 控股股东刘方毅先生资信状况良好，具备良好的资金偿还能力， 本次解除质押后，其剩余质押股份不存在实质性资金偿还风险，所质 押的股份目前不存在平仓风险或被强制过户的情形，质押风险可控， 不会对公司生产经营、公司治理等产生影响。公司将持续关注其质押 情况及质押风险情况，并按规定及时做好相关信息披露工作，敬请投 资者注意投资风险。 四、备查文件 1、中国证券登记结算有限责任公司深圳分公司证券质押及司法 冻结明细表； 2 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-145 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 英科医疗科技股份有限公司 关于 2022 年限制性股票激励计划第三期 解除限售股份上市流通提示性公告 1、本次符合解除限售条件的激励对象共计 535 人，实际解除限 售股份数量为 1,052,520 股，占公司当前股本总额的 0.1607%。 2、本次解除限售的限制性股票解除限售日即上市流通日为 2025 年 10 月 29 日。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 20 日召开了第四届董事会第十一次会议，审议通过了《关于公司 2022 年限制性股票激励计划第三期解除限售条件成就的议案》，并 根据公司 2022 年第二次临时股东大会的授权依照的相关规定，办理 了解除限售股份上市流通的相关事宜，现就有关事项公告如下： 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 1、2022 年 6 月 9 日，公司召开第三届董事会第三次会议及第三 届监事会第三次会议，审议通过了《关于公司<2022 年 ...

关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300677 证券简称：英科医疗 公告编号：2025-144 英科医疗科技股份有限公司 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担 ...

Core Viewpoint - The stock of Yingke Medical (300677) has experienced a decline, with a closing price of 40.71 yuan on October 22, 2025, down 2.28% from the previous day, indicating a trend of net outflow of major funds and mixed retail investor activity [1][2][3]. Financial Performance - Yingke Medical reported a main business revenue of 4.913 billion yuan for the first half of 2025, an increase of 8.9% year-on-year, and a net profit attributable to shareholders of 710 million yuan, up 21.02% year-on-year [5]. - The company's second-quarter revenue was 2.42 billion yuan, reflecting a year-on-year increase of 4.79%, while the net profit for the quarter was 358 million yuan, up 2.55% year-on-year [5]. - The company's gross profit margin stands at 24.23%, which is significantly lower than the industry average of 51.42% [5]. Market Activity - On October 22, 2025, major funds saw a net outflow of 64.62 million yuan, accounting for 9.65% of the total transaction amount, while retail investors had a net inflow of 44.77 million yuan, representing 6.68% of the total [1][2]. - The financing data indicates a net repayment of 7.75 million yuan on October 22, with a total financing balance of 860 million yuan [3]. Industry Comparison - Yingke Medical's total market capitalization is 26.657 billion yuan, significantly higher than the industry average of 11.613 billion yuan, ranking 8th in the industry [5]. - The company has a price-to-earnings ratio of 18.76, which is favorable compared to the industry average of 120.11, ranking 7th [5]. - The return on equity (ROE) for Yingke Medical is 4.03%, outperforming the industry average of 1.91%, ranking 43rd [5].

Core Insights - As of October 21, a total of 66 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Fanwei Network, which has seen net buying for 10 trading days [1] - Other notable stocks with significant consecutive net inflows include Mindray Medical, Yingke Medical, Shenjian Co., Xingqi Eye Medicine, Maixinlin, Deep Technology, Diweier, and Haide Co. [1]